Background
SURPASS-2 was a landmark head-to-head comparison between tirzepatide — the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — and subcutaneous semaglutide 1 mg (Ozempic), the leading GLP-1 receptor agonist for type 2 diabetes management. The trial addressed the central scientific and clinical question: does dual GIP/GLP-1 receptor co-agonism produce superior glycemic and weight outcomes compared to selective GLP-1 receptor agonism?
The mechanistic hypothesis was that GIP receptor activation, in combination with GLP-1 receptor activation, would provide additive or synergistic benefits through complementary incretins pathways — GIP acting on adipose tissue and potentially potentiating GLP-1-mediated insulin secretion, while both hormones act on the CNS appetite regulation centers.
Methods
Design: Multicenter, open-label, active-comparator-controlled randomized trial (open-label due to different injection volumes and titration schedules)
Population: 1,879 adults with T2D inadequately controlled on metformin alone; HbA1c 7.5–11.0%, BMI ≥25 kg/m²
Treatment arms:
- Tirzepatide 5 mg/week (n=470)
- Tirzepatide 10 mg/week (n=469)
- Tirzepatide 15 mg/week (n=470)
- Semaglutide 1 mg/week (n=470) — the comparator
Duration: 40 weeks
Primary endpoint: Change in HbA1c from baseline
Key secondary: Change in body weight; proportion achieving HbA1c <7.0%; proportion achieving ≥5% or ≥10% weight loss
Key Findings
HbA1c Reduction (Primary Endpoint):
| Treatment | HbA1c Change | vs. Semaglutide |
|---|---|---|
| Tirzepatide 5 mg | −2.09% | −0.23% (p < 0.001) |
| Tirzepatide 10 mg | −2.37% | −0.51% (p < 0.001) |
| Tirzepatide 15 mg | −2.46% | −0.60% (p < 0.001) |
| Semaglutide 1 mg | −1.86% | — |
All three tirzepatide doses were statistically superior to semaglutide for HbA1c reduction.
Body Weight Reduction (Secondary Endpoint):
| Treatment | Weight Change | vs. Semaglutide |
|---|---|---|
| Tirzepatide 5 mg | −7.6 kg | −2.1 kg (p < 0.001) |
| Tirzepatide 10 mg | −9.3 kg | −3.8 kg (p < 0.001) |
| Tirzepatide 15 mg | −13.9 kg | −8.4 kg (p < 0.001) |
| Semaglutide 1 mg | −5.5 kg | — |
Proportion Achieving Targets:
| Outcome | Tirzepatide 15 mg | Semaglutide 1 mg |
|---|---|---|
| HbA1c < 7.0% | 92% | 81% |
| HbA1c ≤ 6.5% (normal) | 63% | 35% |
| ≥5% weight loss | 80% | 55% |
| ≥10% weight loss | 53% | 25% |
| ≥15% weight loss | 27% | 8% |
Cardiometabolic Parameters:
| Parameter | Tirzepatide 15 mg | Semaglutide 1 mg |
|---|---|---|
| Systolic BP (mmHg) | −6.0 | −3.5 |
| Triglycerides | −24% | −14% |
| HDL-C | +10% | +6% |
Safety:
- Nausea: 22% tirzepatide 15 mg vs 18% semaglutide (similar profile)
- Diarrhea: 13% vs 12%
- Vomiting: 8% vs 8%
- Hypoglycemia (< 54 mg/dL): 0.6% tirzepatide vs 0.4% semaglutide (low rates, both on metformin only)
- Discontinuation due to GI AEs: 6.3% tirzepatide 15 mg vs 4.3% semaglutide
Mechanism: Dual GIP/GLP-1 Co-Agonism
Tirzepatide’s superior efficacy over semaglutide (a selective GLP-1 agonist) demonstrates that GIP receptor co-activation provides clinically meaningful additive effects:
- Adipose tissue GIP signaling: GIP receptors on adipocytes may facilitate fat mobilization and lipid clearance, complementing GLP-1’s central appetite suppression
- Synergistic insulin secretion: GIP and GLP-1 act via different G-protein pathways (Gs and Gq) in beta cells — combined activation amplifies glucose-stimulated insulin secretion beyond either alone
- Central appetite regulation: Both GIP and GLP-1 receptors are expressed in hypothalamic appetite circuits; dual activation produces greater satiety signaling
- Glucagon suppression: Both incretin hormones suppress glucagon — dual agonism provides more complete post-meal glucagon suppression
Clinical Significance
- First superior head-to-head over semaglutide: SURPASS-2 established that dual GIP/GLP-1 co-agonism meaningfully outperforms best-in-class GLP-1 monotherapy — a paradigm shift in incretin pharmacology
- Weight loss magnitude: Tirzepatide 15 mg produced −13.9 kg mean weight loss in T2D patients on metformin — approaching the weight outcomes previously achievable only with bariatric surgery or anti-obesity medicines in non-diabetic populations
- Normoglycemia at scale: 63% of tirzepatide 15 mg recipients achieved HbA1c ≤6.5% — unprecedented pharmacological normalization of blood glucose in T2D
- Regulatory implications: SURPASS-2 data contributed to FDA approval of tirzepatide (Mounjaro) for T2D and provided the head-to-head evidence basis for comparative effectiveness discussions with payers
Limitations
- Open-label design introduces potential performance bias in patient self-reporting and adherence (necessary given different injection volumes between tirzepatide doses and semaglutide)
- Semaglutide comparator was 1 mg (standard T2D dose) — the higher 2.4 mg weight management dose (Wegovy) was not compared; outcomes against weight management semaglutide would require separate head-to-head data
- 40-week duration; longer-term outcomes, particularly cardiovascular events, require dedicated CVOT (the SURPASS-CVOT and SURMOUNT-5 trials address this)
- Predominantly White population (60%); metabolic responses and adverse event profiles may differ across racial/ethnic groups
- Metformin background only — results in patients on other antidiabetic agents (SGLT-2i, sulfonylurea) may differ